MGX

Metagenomi Therapeutics, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$0.71

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0 / %30

Non-compliant assets / Total market cap %68.6 / %30

Non-compliant revenue / Total income %100 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia.

Website

Analysis (Turkish): MGX Hissesi Caiz mi, Helal mi? Metagenomi Therapeutics, Inc. Katılım Analizi